542,791 Shares in Elanco Animal Health Incorporated (NYSE:ELAN) Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH has acquired a stake of approximately $5.70 million in Elanco Animal Health, purchasing 542,791 shares, representing about 0.11% of the company.
• Elanco's quarterly earnings report revealed $0.37 earnings per share, exceeding analysts' expectations of $0.31, with revenue also surpassing estimates at $1.19 billion.
• Recent analyst upgrades have led to a positive outlook for Elanco, with most firms giving it a "Moderate Buy" rating and a consensus price target of $16.17.

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 542,791 shares of the company's stock, valued at approximately $5,699,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.11% of Elanco Animal Health as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. American Century Companies Inc. raised its stake in shares of Elanco Animal Health by 1.8% during the fourth quarter. American Century Companies Inc. now owns 128,264 shares of the company's stock valued at $1,553,000 after purchasing an additional 2,280 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Elanco Animal Health during the 4th quarter valued at $1,232,000. LPL Financial LLC grew its holdings in shares of Elanco Animal Health by 15.9% during the 4th quarter. LPL Financial LLC now owns 161,183 shares of the company's stock valued at $1,952,000 after acquiring an additional 22,163 shares in the last quarter. WINTON GROUP Ltd bought a new stake in Elanco Animal Health in the fourth quarter worth $141,000. Finally, Blair William & Co. IL boosted its holdings in Elanco Animal Health by 17.3% during the fourth quarter. Blair William & Co. IL now owns 70,430 shares of the company's stock valued at $853,000 after acquiring an additional 10,400 shares during the period. 97.48% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on ELAN shares. Leerink Partnrs upgraded shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 17th. William Blair raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a report on Thursday, June 26th. Stifel Nicolaus raised their price target on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a report on Wednesday, July 2nd. Wall Street Zen raised shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Finally, UBS Group lifted their price target on shares of Elanco Animal Health from $17.00 to $18.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $16.17.

Elanco Animal Health Stock Performance

Shares of NYSE ELAN traded down $0.07 during midday trading on Thursday, hitting $14.06. The company's stock had a trading volume of 1,032,392 shares, compared to its average volume of 5,267,297. The stock has a fifty day moving average price of $14.09 and a 200 day moving average price of $11.95. The firm has a market capitalization of $6.98 billion, a price-to-earnings ratio of 18.99, a P/E/G ratio of 2.81 and a beta of 1.67. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $15.78. The company has a current ratio of 2.71, a quick ratio of 1.46 and a debt-to-equity ratio of 0.68.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, topping analysts' consensus estimates of $0.31 by $0.06. The firm had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.17 billion. Elanco Animal Health had a return on equity of 7.54% and a net margin of 8.43%. The business's revenue for the quarter was down 1.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.34 EPS. On average, research analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.